Klech H, Rona G, Hutter C, Bayer P M, Kummer F
Wien Klin Wochenschr. 1986 Sep 12;98(17):564-73.
Measurement of carcinoembryonal (CEA) levels in pleural fluid are suggested to improve the unsatisfactory sensitivity of pleural cytology in the differential diagnosis of malignant pleural effusions. We evaluated simultaneously determined pleural and serum CEA levels in 117 patients with pleural effusions of different aetiology (74 malignant, 30 inflammatory exudates and 13 transudates) by use of an enzyme immunoassay (EIA). Despite considerable scatter, pleural levels of CEA in malignant effusions were significantly higher (p less than 0.001) than the values in benign effusions. Using a cut off level of 5 ng/ml, 41% (= sensitivity) of malignant pleural effusions showed elevated concentrations of CEA. Only one out of 43 benign effusions showed a level of 5 ng/ml, which is equivalent to a specificity of 98%. However, malignant effusions due to small cell lung cancer, pleural mesothelioma and metastasising ovarian carcinoma never showed elevated levels of CEA. Highest pleural values of CEA were observed in cases of alveolar cell or adenocarcinoma of the lung or metastasising breast cancer. Although pleural and serum CEA levels correlated significantly (rs = 0.77), the evaluation of serum CEA levels alone yielded a lower sensitivity (36%) and specificity (93%) than pleural levels. 77% of cases with malignant pleural effusions showing elevated pleural CEA levels were characterized by an increased ratio Pleura/Serum greater than 1, particularly in effusions due to lung cancer. The CEA ratio was significantly higher (p less than 0.05) in patients with malignant than with benign effusions. EIA appears to be more specific by avoiding false positive results in benign effusions as compared with determination by conventional RIA. In conclusion, evaluation of pleural CEA levels in patients with malignant effusions by using an EIA because of its high specificity is a valuable adjunct to pleural cytology in improving the diagnosis of malignant effusions. However, a normal CEA level in either pleural effusion or in serum is of no clinical significance. Simultaneous measurement in pleural effusion and serum is of greater value.
建议检测胸水癌胚抗原(CEA)水平,以改善胸水细胞学检查在恶性胸腔积液鉴别诊断中敏感性欠佳的情况。我们采用酶免疫分析法(EIA),同时检测了117例不同病因胸腔积液患者(74例恶性、30例炎性渗出液和13例漏出液)的胸水和血清CEA水平。尽管存在较大离散度,但恶性胸腔积液的胸水CEA水平显著高于良性胸腔积液(p<0.001)。以5 ng/ml为临界值,41%的恶性胸腔积液(即敏感性)CEA浓度升高。43例良性胸腔积液中只有1例CEA水平为5 ng/ml,特异性为98%。然而,小细胞肺癌、胸膜间皮瘤和转移性卵巢癌所致的恶性胸腔积液CEA水平从未升高。CEA胸水最高值见于肺泡细胞癌、肺腺癌或转移性乳腺癌患者。尽管胸水和血清CEA水平显著相关(rs=0.77),但单独检测血清CEA水平的敏感性(36%)和特异性(93%)低于胸水水平。77%恶性胸腔积液胸水CEA水平升高的病例,其胸水/血清比值大于1,尤其是肺癌所致胸腔积液。恶性胸腔积液患者的CEA比值显著高于良性胸腔积液患者(p<0.05)。与传统放射免疫分析法(RIA)相比,EIA通过避免良性胸腔积液出现假阳性结果,似乎更具特异性。总之,由于EIA具有高特异性,检测恶性胸腔积液患者的胸水CEA水平,是提高恶性胸腔积液诊断的有价值的辅助手段,可作为胸水细胞学检查的补充。然而,胸水或血清中CEA水平正常并无临床意义。同时检测胸水和血清更有价值。